Optimized for existing workflows on the company's LeviCell platform, the tissue dissociation kits are designed to provide gentler end-to-end handling across a range of human and model tissue types, including tumor, heart, liver, lung, kidney, and brain, according to the company. The kits enable high viability suspended cell enrichment to be obtained while minimizing cell stress, damage, or population bias, the company said.

LevitasBio's new target depletion assays remove specific, selectable background targets from the sample during the enrichment process on LeviCell, which in turn facilitates viable cell enrichment, debris removal, and targeted background depletion in a single step, according to the firm.

Both products will be available commercially in the first half of 2022.